News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2017

June

Media Release / Jun 22, 2017

Top 10 Novartis Facts and Figures

Read More
Media Release / Jun 20, 2017

PrXolair® added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)

Read More
Media Release / Jun 19, 2017

Combination treatment PrTafinlar® (dabrafenib) plus PrMekinist® (trametinib) approved by Health Canada to treat BRAF V600-positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy1

Read More
Media Release / Jun 15, 2017

Combination treatment (Pr)Tafinlar® (dabrafenib) plus (Pr)Mekinist® (trametinib) approved by Health Canada to treat BRAF V600- positive metastatic non-small cell lung cancer (NSCLC) after prior systemic therapy

Read More

May

Media Release / May 11, 2017

21 years of community service: Novartis takes part in annual Community Partnership Day in Canada

Read More
Media Release / May 09, 2017

Novartis heart failure treatment PrEntresto™ (sacubitril/valsartan) now available to patients in Ontario through the public provincial drug plan

Read More
Media Release / May 03, 2017

Montrealer Janice Murray named President of Novartis in Canada

Read More

March

Media Release / Mar 23, 2017

Novartis heart failure treatment PrEntresto™ (sacubitril/valsartan) now covered by the Régie de l'assurance maladie du Québec (RAMQ)*

Read More
Media Release / Mar 09, 2017

New Entresto™ Analysis

Optimal use of Novartis heart failure treatment (Pr)Entresto™ could save more than 3,000 lives in Canada each year according to a new analysis1

Read More
2016

August

Media Release / Aug 23, 2016

Novartis employees return from volunteer healthcare mission in rural Kenya

Read More

Pages